<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Savara, Inc.

    Savara, Inc.

    Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex,...

    Savara is an orphan lung disease company. Savar...

    Filing Type:    PU
    Dova Pharmaceuticals, Inc.

    Dova Pharmaceuticals, Inc.

    Dova is a pharmaceutical company focused on acquiring, developing and commercializ...

    Dova is a pharmaceutical company focused on acq...

    Filing Type:    PU
    Immutep Limited

    Immutep Limited

    We are a biotechnology company developing novel immunotherapy treatments for cance...

    We are a biotechnology company developing novel...

    Filing Type:    PU
    Adaptive Biotechnologies Corporation

    Adaptive Biotechnologies Corporation

    We are a commercial-stage biotech company focused on harnessing the inherent biolo...

    We are a commercial-stage biotech company focus...

    Filing Type:    PU
    Compugen Ltd.

    Compugen Ltd.

    Compugen is a drug discovery company with a unique, broadly applicable, predictive...

    Compugen is a drug discovery company with a uni...

    Filing Type:    PU
    Quadrant Biosciences Inc

    Quadrant Biosciences Inc

    Quadrant Biosciences is an epigenetic diagnostics company with a focus on the earl...

    Quadrant Biosciences is an epigenetic diagnosti...

    Filing Type:    RA
    Jounce Therapeutics, Inc.

    Jounce Therapeutics, Inc.

    Jounce Therapeutics is a clinical stage immunotherapy company dedicated to transfo...

    Jounce Therapeutics is a clinical stage immunot...

    Filing Type:    PU
    BeyondSpring, Inc.

    BeyondSpring, Inc.

    Headquartered in New York, BeyondSpring Inc. (BeyondSpring) is a global, clinical-...

    Headquartered in New York, BeyondSpring Inc. (B...

    Filing Type:    PU
    Neoleukin Therapeutics, Inc.

    Neoleukin Therapeutics, Inc.

    Neoleukin is a biopharmaceutical company creating next generation immunotherapies ...

    Neoleukin is a biopharmaceutical company creati...

    Filing Type:    PU
    Celsion Corporation

    Celsion Corporation

    Celsion Corporation is a fully integrated biopharmaceutical company focused on dev...

    Celsion Corporation is a fully integrated bioph...

    Filing Type:    PU
    AVEO Pharmaceuticals, Inc.

    AVEO Pharmaceuticals, Inc.

    AVEO Pharmaceuticals, Inc. is a biopharmaceutical company seeking to advance targe...

    AVEO Pharmaceuticals, Inc. is a biopharmaceutic...

    Filing Type:    PU
    Tiziana Life Sciences plc

    Tiziana Life Sciences plc

    Tiziana Life Sciences is a dual-listed (NASDAQ:TLSA, AIM:TILS) clinical stage biot...

    Tiziana Life Sciences is a dual-listed (NASDAQ:...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.